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Background and Methods. Advances in immunosuppressive
treatment regimens, with increased efficacy, while minimiz-
ing the treatment-related toxicities, and better prevention and
treatment of complications, have resulted in improved patient
and renal survival in subjects with severe proliferative lupus
nephritis over the past few decades. This review discusses the
issues that are pertinent to the preservation of renal function in
these patients.
Results and Conclusion. Treatment of severe proliferative lu-
pus nephritis can be divided into an initial phase of induction
followed by a prolonged maintenance phase, both of which im-
pact upon the long-term renal and patient survival. The im-
munosuppressive potency of the treatment required for disease
control varies according to the disease activity during the differ-
ent phases. Despite variations in the choice, duration, and route
of administration of antiproliferative agents, data to date sug-
gest that immunosuppresive treatments combining cyclophos-
phamide or mycophenolate mofetil with corticosteroid appear
to have similar efficacy in terms of inducing immunologic re-
mission. In this regard, the immunologic efficacy of treatment
is prerequisite to the prevention of irreversible loss of nephrons,
but long-term renal outcome is also dependent on factors other
than treatment efficacy, such as preexisting renal parenchymal
damage and blood pressure control. Prompt diagnosis, early ef-
fective therapy, and reducing the risk of relapses are the disease
specific measures that are essential to long-term renal preserva-
tion and the prevention of renal failure in subjects with severe
proliferative lupus nephritis.
The outcome of patients with severe proliferative lu-
pus nephritis has improved considerably over the past
few decades. Patient survival rate was 70% at 5 years dur-
ing the 1960s [1], but has been reported to exceed 90% at
10 years in recent series [2, 3]. Factors contributing to this
improvement include advancements in immunosuppres-
sive therapy, as well as better prevention and manage-
ment of complications, such as infection or hypertension.
Immunosuppressive treatment regimens with enhanced
efficacy but reduced adverse effects have evolved from
clinical studies. While the immunosuppressive regimens
remain varied, the commonly adopted immunosuppres-
sive treatments appear to have comparable short-term
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efficacy in inducing remission. In contrast, the long-term
outcome after treatment is less well defined. Despite a
general trend toward progressive improvement in long-
term renal survival, independent investigators have re-
ported different rates of renal failure. The variation in
immunosuppressive treatments represents only one of
many factors that can influence the longitudinal evolu-
tion of renal function.
OUTCOME INDICATORS OF CLINICAL TRIALS
IN LUPUS NEPHRITIS
The incidence of renal failure associated with different
treatments, as indicated by doubling of baseline serum
creatinine level and/or end-stage renal failure, is com-
monly used as the principal end point of studies. In ac-
cordance with the progressive nature of renal function
deterioration, it has been shown that prolonged follow-
up exceeding 5 years is required to discern different treat-
ment outcomes [4]. While these end points have obvious
clinical relevance, it is imperative to note that the ultimate
renal outcome is also under the influence of factors other
than immunosuppressive efficacy. These modulating fac-
tors include the extent of irreversible renal parenchymal
damage before and after induction therapy, blood pres-
sure control, and the number and severity of subsequent
nephritic relapses, which also relate to the efficacy of
maintenance immunosuppression. Therefore, while long-
term renal survival is the ultimate aim of clinical manage-
ment, it is actually a composite end point subject to the
influence of multiple confounding factors.
Prompt induction of remission is the major short-term
objective of immunosuppressive treatment in severe lu-
pus nephritis. The definition of remission varies between
investigators, and commonly adopted criteria include a
significant reduction of proteinuria, reversal of renal fail-
ure or preservation of baseline renal function, and im-
provement of serologic parameters such as the titre of
anti-DNA antibodies and complement components. It
should be noted, however, that the lack of improvements
in proteinuria or renal function after treatment may be
due to delayed treatment and irreversible scarring rather
than inadequate immunosuppressive potency. The effi-
cacy of immunosuppressive treatment per se is evident
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from abatement of serologic activity, which usually pre-
cedes end-organ manifestations. Immunologic remission
is prerequisite to interruption of the damaging inflam-
matory processes. Prompt induction of remission is, thus,
essential to the preservation of a critical renal mass, and
the prevention of progressive renal failure [2].
TREATMENT OUTCOME WITH DIFFERENT
IMMUNOSUPPRESSIVE REGIMENS
Immunosuppressive medications remain the mainstay
of treatment for lupus nephritis. In general, the intensity
of immunosuppressive therapy should be tailored accord-
ing to the serologic and histologic activity. Treatment of
severe proliferative lupus nephritis can be separated into
an initial phase of induction followed by a prolonged
maintenance phase. The aim of induction treatment is
to induce remission and preserve renal parenchyma,
while that of maintenance therapy is to prevent relapses.
Maximizing patient and renal survival, minimizing com-
plications, and avoiding treatment-related adverse effects
remain the unifying themes throughout the course of
management. The induction phase lasts 4 to 6 months,
and the immunosuppressive treatment usually comprises
corticosteroid and an antiproliferative agent [3, 5–7]. Af-
ter the disease activity is under control, the dose of cor-
ticosteroid is reduced and potent immunosuppressive
agents can be replaced by less toxic alternatives.
Prednisolone combined with cyclophosphamide, the
latter either as intermittent intravenous pulses or as daily
oral treatment, has been commonly used as initial treat-
ment [6, 8]. The inclusion of cyclophosphamide has been
associated with better renal preservation and more sta-
ble remissions compared with corticosteroid treatment
alone. A series of clinical trials from investigators at
the NIH have shown that induction treatment with in-
travenous cyclophosphamide pulses was more effective
than pulse methylprednisolone alone, and was associ-
ated with fewer side effects compared with prolonged
(often exceeding 1 year) daily oral cyclophosphamide
treatment [4, 9, 10]. In addition, extending the duration of
intravenous cyclophosphamide treatment with quarterly
pulses for 2 years reduced the relapse rate but increased
the risk of ovarian failure, compared with treatment that
included only the initial 6 monthly pulses [10]. Recently
the Euro-lupus Nephritis Trial showed that low-dose in-
travenous cyclophosphamide pulses of 500 mg fortnightly
for 6 doses followed by azathioprine maintenance was as
effective as the NIH regimen and might be associated
with fewer infections [11]. Our own data showed that se-
quential immunosuppression with prednisolone and oral
cyclophosphamide followed by low-dose prednisolone
and azathioprine maintenance was associated with a com-
plete remission rate of 77%, and that severe toxicities
such as hemorrhagic cystitis or permanent amenorrhea
could be obviated by limiting the duration of cyclophos-
phamide treatment to 6 months [12]. For comparison,
a remission rate of 78% at 2 years has been reported
in patients treated with prednisone and intravenous cy-
clophosphamide [13], and a complete remission rate of
around 50% has been observed in patients treated with
pulse cyclophosphamide, pulse methylprednisolone, or
the combination of both [14]. A retrospective study on
43 subjects over 24 months has reported comparable re-
mission rates of 73% and 90% in patients treated with
intravenous or oral cyclophosphamide, respectively [15].
While patient characteristics and the definitions of remis-
sion differed between the various series, these data sug-
gest that the duration of cyclophosphamide treatment is
more important than its route of administration on the
incidence of severe adverse effects.
Our previous studies on sequential immunosuppres-
sion with prednisolone and oral cyclophosphamide for
6 months followed by azathioprine maintenance showed
that renal function remained stable during 35 months of
follow-up [12]. In a follow-up study involving 66 patients
with follow-up of more than 7 years, we have observed
that the promising short-term outcome was associated
with long-term stability of renal function in the majority
of patients, so that chronic renal failure was noted in 6%
of patients, and there was no death or end-stage renal
failure [16]. In this context, other investigators have re-
ported that 20% to 30% of patients treated with corticos-
teroid and intravenous cyclophosphamide pulses showed
doubling of baseline serum creatinine after 36 months
[10], and after 117 months, 21.4% of patients had died or
developed end-stage renal failure, while another 11.7%
showed chronic renal failure [14]. Another study reported
that 12.8% of patients developed end-stage renal fail-
ure, and 8.1% had chronic renal failure after 2.6 years
of follow-up following treatment with prednisone and
8 weeks of oral cyclophosphamide [5]. A study on 21
Chinese patients treated with a similar sequential im-
munosuppression regimen showed that 9.5% of patients
had treatment failure or doubling of serum creatinine by
24 months [15]. These differences may be related to vari-
ations in clinical or histologic characteristics, sample size,
ethnicity, and other factors that can influence long-term
outcome.
More recently, we have shown that mycophenolate
mofetil provides an equally effective alternative to cy-
clophosphamide, but with distinctly fewer and less se-
vere side effects [17]. Patients treated with sequential
immunosuppression and those treated with prednisolone
and mycophenolate mofetil had similar remission rates of
around 80%, and similar renal function during 12 months
of follow-up. Mycophenolate mofetil treated subjects had
fewer infections, no significant alopecia, or leukopenia,
compared to those treated with cyclophosphamide. A
follow-up study with a bigger sample size and follow-up
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Prednisolone 0.8 mg/kg/day, tapered to 7.5–10 mg/day
after 4–6 months
Mycophenolate mofetil 1.0–1.5 g b.i.d. for 6 months
or
Cyclophosphamide i.v. 0.5–1 g/m2/month for 6 months or
500 mg fortnightly for 6 doses, or p.o.
2–2.5 mg/kg/day for 4–6 months
Maintenance
Prednisolone 7.5 mg/day gradually reduced to
5 mg/day
Azathioprine 2–2.5 mg/kg/day gradually reduced to 1
mg/kg/day, optimal duration not well
defined
or
Mycophenolate mofetil 1.0 g b.i.d. gradually reduced to 0.5 g
b.i.d., optimal duration not well
defined
or
Cyclophosphamide i.v. 0.5–1 g/m2 every 3 months for up to
2 doses
exceeding 5 years showed similar relapse rates and a low
incidence of renal failure (<10%) in both groups (un-
published data). Other investigators have reported that,
following induction with corticosteroid and intravenous
pulse cyclophosphamide, patients maintained on quar-
terly pulses of intravenous cyclophosphamide showed
a higher incidence of death or renal failure compared
with those who received maintenance treatment with my-
cophenolate mofetil or azathioprine [18]. The apparently
lower relapse rate with mycophenolate mofetil mainte-
nance needs to be confirmed in bigger series. Neverthe-
less, it is likely that in combination with corticosteroid
mycophenolate mofetil will replace cyclophosphamide as
standard therapy for severe lupus nephritis (Table 1).
FACTORS THAT INFLUENCE LONG-TERM
RENAL SURVIVAL
Factors that have been reported to adversely affect re-
nal survival in patients with severe proliferative lupus
nephritis include a high chronicity index and impaired
renal function at baseline, failure to achieve complete
remission after treatment, and serum creatinine concen-
tration exceeding 2.0 mg/dL after treatment [2, 14, 19].
Lower remission rates have been observed in patients of
African origin compared with Caucasians [2, 14]. In addi-
tion, there is an association between lower socioeconomic
status and inferior long-term outcome, which may be re-
lated at least in part to the timeliness of diagnosis (and
thus treatment) and drug compliance [2, 14, 19, 20]. Simi-
lar to others, we have noted no association between base-
line activity score and long-term renal outcome [14]. This
underscores the importance of reversibility and remis-
sion as critical determinants of final renal outcome. Our
data show an association between the latest renal function
and the renal function both at baseline and at 1 year after
treatment, and that the chronicity index at baseline is also
an independent predictor of latest creatinine clearance.
Together these findings corroborate the important long-
term implications of established renal parenchymal dam-
age, and the critical need to preserve nephrons by prompt
induction of remission. While focal proliferative and dif-
fuse proliferative types of lupus nephritis have long been
regarded as belonging to the same continuum, the Lupus
Nephritis Collaborative Study Group has recently pre-
sented data to suggest that the two might have distinct
pathogenetic mechanisms, so that focal proliferative le-
sions were associated with a lower likelihood of complete
remission and a higher risk of renal failure compared with
diffuse proliferative disease [21].
Relapses are common in systemic lupus erythematosus,
and nephritic relapses adversely affect long-term renal
outcome because with each relapse there is immune-
mediated renal damage [14, 22]. It is therefore imperative
to watch out for impending relapse by regular monitoring
of serologic and clinical parameters. It remains controver-
sial whether to increase the dose of immunosuppression
preemptively should there be serologic reactivation in the
absence of clinical manifestations. Such decisions should
be individualized, taking into account the previous his-
tory of relapses. Our own data on patients treated with
sequential immunosuppression show that 39% of patients
relapsed over 7 years. This relapse rate appears compa-
rable to that observed in patients who have received in-
travenous cyclophosphamide as induction therapy [13].
The relatively late occurrence (median of 79 months) of
relapses in the latter study could be attributed to the long
duration of cyclophosphamide treatment lasting 3 years.
A relapse rate of 45% was reported in another study that
included patients treated with pulse cyclophosphamide,
pulse methylprednisolone, or the combination of both
[9]. Similar to our findings, this study also reported an
increased risk of relapse in patients who failed to achieve
complete remission. Although nephritic relapses might
result in reduced renal reserve, it is of interest to note that
the latest renal function is similar between relapsers and
nonrelapsers in our own series. This apparent paradox
may be explained by the mild nature of the relapses, their
early detection, and prompt reinduction of remission. The
optimal rate of dose tapering, and the relative merits of
low-dose prednisolone with or without mycophenolate
mofetil or azathioprine as maintenance treatment, all re-
quire further investigation.
Hypertension and hyperlipidemia affect about one
third and one fifth of patients with a history of lupus
nephritis, respectively. The detrimental effect of uncon-
trolled hypertension on accelerating renal deterioration
is well recognized. There is increasing evidence that heavy
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proteinuria per se can exacerbate tubulointerstitial in-
flammation and fibrosis [23–25]. Although there is little
data on the effect of angiotensin II blockade on protein-
uria or renal protection in patients with lupus nephritis,
this seems a reasonable approach in patients with persis-
tent proteinuria despite optimal control of disease activ-
ity. It is imperative that these complications are rigorously
prevented and controlled, since these patients show ac-
celerated atherosclerosis and coronary vascular disease,
which lead to premature vascular morbidity and mortal-
ity [26, 27]. Cardiovascular events have been reported to
account for 48% of deaths in patients with a history of
lupus nephritis [19, 28].
CONCLUSION
Management of patients with lupus nephritis encom-
passes both immunosuppressive therapy and the preven-
tion and treatment of complications related to disease or
treatment, with the ultimate aim of maximizing patient
survival, renal survival, quality of life, and rehabilitation.
With the advent of potent immunosuppressive agents,
death from uncontrolled lupus activity is increasingly un-
common, although severe extrarenal involvements, such
as pulmonary or cerebral lupus, are still associated with
considerable morbidity and mortality. A recent report has
shown that the outcome of patients with lupus nephritis
who presented during the last decade was better than
those who presented in the 1980s [29], and that such im-
provement was related to shorter time to diagnosis, less
severe proteinuria, and fewer chronicity features at diag-
nosis. These findings exemplify the importance of early
diagnosis and early intervention with effective but safe
immunosuppression, before the disease activity has cul-
minated in significant irreversible end-organ damage.
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